85 related articles for article (PubMed ID: 28959338)
1. Generating pathways to domestically sourced plasma-derived medicinal products: Report from a workshop by the International Plasma and Fractionation Association and the Working Party on Global Blood Safety of the International Society of Blood Transfusion.
Farrugia A; Perry R; Rossi F; von Bonsdorff L; Bowie G; Faber JC; Omarjee JH; Epstein J; White J
Vox Sang; 2024 Jun; ():. PubMed ID: 38925641
[TBL] [Abstract][Full Text] [Related]
2. Advances and challenges in the purification of recombinant coagulation factors: A review.
Yu L; Yang D; Chu M; Sun Y
J Chromatogr A; 2024 Feb; 1716():464662. PubMed ID: 38244305
[TBL] [Abstract][Full Text] [Related]
3. Current and emerging factor VIII replacement products for hemophilia A.
Cafuir LA; Kempton CL
Ther Adv Hematol; 2017 Oct; 8(10):303-313. PubMed ID: 29051801
[TBL] [Abstract][Full Text] [Related]
4. The Evolution of the Safety of Plasma Products from Pathogen Transmission-A Continuing Narrative.
Farrugia A
Pathogens; 2023 Feb; 12(2):. PubMed ID: 36839590
[TBL] [Abstract][Full Text] [Related]
5. The effect of donor's characteristics on plasmapheresis products: insights for a personalised approach.
Merolle L; Marraccini C; Vurro F; Parisi M; Di Bartolomeo E; Bonvicini L; Broccoli S; Rossi PG; Baricchi R; Pertinhez TA
Blood Transfus; 2020 May; 18(3):170-175. PubMed ID: 32281927
[TBL] [Abstract][Full Text] [Related]
6. Implementation of Plasma Fractionation in Biological Medicines Production.
Mousavi Hosseini K; Ghasemzadeh M
Iran J Biotechnol; 2016 Dec; 14(4):213-220. PubMed ID: 28959338
[TBL] [Abstract][Full Text] [Related]
7. [Plasma fractionation in the world: current status].
Burnouf T
Transfus Clin Biol; 2007 May; 14(1):41-50. PubMed ID: 17499539
[TBL] [Abstract][Full Text] [Related]
8. [Blood protein technological industrial developments as a mirror of fundamental studies bgy the Institute of Biochemistry of the Ukrainian National Academy of Sciences].
Volkov GL; Andrianov SI; Horoshnykova TV; Borysevych OS; Gavryliuk OS
Ukr Biokhim Zh (1999); 2000; 72(4-5):109-21. PubMed ID: 11200439
[TBL] [Abstract][Full Text] [Related]
9. Polyacrylic acid based plasma fractionation for the production of albumin and IgG: Compatibility with existing commercial downstream processes.
McCann KB; Van Alstine J; Martinez J; Shanagar J; Bertolini J
Biotechnol Bioeng; 2020 Apr; 117(4):1072-1081. PubMed ID: 31930475
[TBL] [Abstract][Full Text] [Related]
10. Chromatography in plasma fractionation: benefits and future trends.
Burnouf T
J Chromatogr B Biomed Appl; 1995 Feb; 664(1):3-15. PubMed ID: 7757237
[TBL] [Abstract][Full Text] [Related]
11. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
12. Preparation of factor VII concentrate using CNBr-activated Sepharose 4B immunoaffinity chromatography.
Mousavi Hosseini K; Nasiri S
Med J Islam Repub Iran; 2015; 29():170. PubMed ID: 26034723
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of model viruses suspended in fresh frozen plasma using novel methylene blue based device.
Elikaei A; Sharifi Z; Hosseini SM; Latifi H; Musavi Hosseini MK
Iran J Microbiol; 2014 Feb; 6(1):41-5. PubMed ID: 25954491
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
